8-K: VivoSim Labs Faces Nasdaq Listing Concern, Plans Compliance

VivoSim Labs received a notice from Nasdaq for failing to meet minimum stockholders equity requirements but has a plan to regain compliance, bolstered by recent transactions.

Summary

• VivoSim Labs received a notice from Nasdaq on July 20, 2026, indicating it no longer meets the minimum stockholders equity requirement of $2,500,000, as its equity was reported as $(1,099,000) in its latest 10-K.
• The company has until September 3, 2026, to submit a plan to Nasdaq to regain compliance.
• If the plan is accepted, Nasdaq may grant an extension of up to 180 days (until January 16, 2027) to achieve compliance.
• The company's stockholders equity has since increased to over $2.5 million due to recent transactions, including a $5.0 million milestone payment from Eli Lilly and the exercise of common warrants.
• The notice does not immediately affect the listing or trading of VivoSim Labs' common stock on the Nasdaq Capital Market under the symbol VIVS.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; while the company received a critical Nasdaq notice, it has taken immediate steps to rectify the situation and has bolstered its equity position, though future compliance remains uncertain.

Positives

• Stockholders equity has increased to over $2.5 million as of the filing date, exceeding the Nasdaq minimum requirement.
• Received a $5.0 million milestone payment from Eli Lilly and Company.
• Successfully closed a private placement on July 17, 2026, raising approximately $4.0 million in gross proceeds.
• Exercised common warrants resulted in an increase to stockholders equity of approximately $5.1 million.

Negatives

• Received a written notice from Nasdaq on July 20, 2026, for failing to meet the minimum stockholders equity requirement of $2,500,000.
• Reported stockholders equity of $(1,099,000) in its Annual Report on Form 10-K for the period ended March 31, 2026.
• The company may face delisting if its compliance plan is not accepted by Nasdaq or if it fails to regain compliance within the specified timeframe.

Risks

• Failure to submit an acceptable plan to Nasdaq to regain compliance with Rule 5550(b)(1) by September 3, 2026.
• Inability to maintain compliance with Nasdaq's minimum stockholders equity requirement or any other Nasdaq listing standards in the future.
• Potential delisting from the Nasdaq Capital Market if compliance is not achieved.
• Uncertainty regarding Nasdaq's acceptance of the company's compliance plan and any potential relief granted.

Future Outlook

The company intends to submit a plan to Nasdaq to regain compliance with listing rules. There is no assurance that Nasdaq will accept the plan or that the company will be able to maintain compliance with Nasdaq requirements in the future. The company assumes no obligation to publicly update forward-looking statements.

Management Comments

• The Company has 45 calendar days from July 20, 2026, or until September 3, 2026, to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1).
• If Nasdaq accepts the Company's plan, Nasdaq may grant an extension of up to 180 calendar days from July 20, 2026, or until January 16, 2027, to regain compliance.
• Although the Company intends to submit to Nasdaq, within the requisite time period, a plan to regain compliance with Rule 5550(b)(1), as of the date of this filing, the Company's stockholders equity is in excess of $2.5 million, as a result of certain transactions described below in Item 8.01.
• There can be no assurance that Nasdaq will accept the Company's plan or that the Company will be able to maintain compliance with Rule 5550(b)(1) or maintain compliance with any other Nasdaq requirement in the future.

Industry Context

StockSavvy.ai notes that Nasdaq listing rule compliance, particularly regarding minimum stockholders equity, is a common challenge for early-stage or development-focused biotechnology companies. The ability to raise capital through private placements and warrant exercises, as demonstrated by VivoSim Labs, is crucial for navigating these periods.

Stakeholder Impact

• Shareholders: Potential short-term volatility in stock price due to the Nasdaq notice, but also potential positive impact if compliance is regained. Dilution concerns may arise from recent capital raises.
• Creditors: The company's ability to maintain its Nasdaq listing is important for its ongoing operations and access to capital markets, which indirectly affects creditors.
• Employees: Continued listing on Nasdaq provides stability and confidence in the company's future, which is important for employee morale and retention.

Next Steps

• Submit a plan to Nasdaq to regain compliance with Rule 5550(b)(1) by September 3, 2026.
• Work towards meeting Nasdaq's minimum stockholders equity requirement by January 16, 2027, if the plan is accepted.
• Continue to monitor and ensure compliance with all Nasdaq listing requirements.

Key Dates

Recommendation

The company is facing a critical Nasdaq listing issue, which introduces significant risk. However, recent capital raises and a plan to address the equity shortfall provide some mitigation. A 'hold' recommendation is appropriate pending clarity on Nasdaq's decision regarding the compliance plan and the company's ability to sustain compliance.

Keywords

Nasdaq compliance, Stockholders equity, Delisting notice, Form 8-K, Capital raise, Milestone payment, Warrant exercise, VivoSim Labs